LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Company News/New Investment by Parvizi Surgical Innovation
Company News

New Investment by Parvizi Surgical Innovation

March 6, 2020 2 min read Premium comments

Advertisement

New Investment by Parvizi Surgical Innovation
Courtesy of Parvizi Surgical Innovation
Secondary#parvizisurgicalinnovation#navbitholdings#singleusesurgicalnavigationsystem

Parvizi Surgical Innovation, LLC has announced an investment in a development-stage hip replacement surgery device company based in Sydney, Australia, named Navbit Holdings Pty Ltd.

Founded in 2015 by Professors Bill and Lynette Walter, Navbit is developing a disposable, single-use surgical device to assist orthopedic surgeons in correctly positioning acetabular cups during hip replacement surgery. The Walters are lead developers of the device, named the Navbit Sprint. The Navbit Sprint is designed to lower the risk of dislocation, which is the most common cause of failure of hip replacement surgery.

“The issue of dislocation after hip replacement is a real one and needs to benefit from technological advancement,” said Professor Walter. “We have developed a disposable, simple to use technology that combines sophistication of software to deliver accuracy while preserving the flow of the surgery and importance of practicality and reproducibility.”

Lynette Walter, CEO, and co-founder of Navbit, told OTW, “We develop products which use cutting edge sensor technologies from the fast-moving consumer tech industry. Navbit Sprint is an affordable technology that assists surgeons with the correct positioning of components during hip replacement. By assisting surgeons to more reliably and accurately place the implant, we expect to reduce the risk of post-operative dislocation.”

Walter continued, “A compact, fully disposable product in-a-box, Navbit Sprint provides an excellent new offering, one which is extremely simple for the surgeon to use, affordable and easy for the hospital to deal with—and of course better for patients. The technology is currently under review with the FDA.”

Alan Miller, president Parvizi Surgical Innovation, spoke to OTW about the investment in Navbit. He said, “Parvizi Surgical Innovation continues in its mission to invest in companies and technologies with the potential to improve the lives of patients and their families. We are proud to partner with Navbit to improve patient outcomes during hip replacement surgery.”

Philadelphia-based Parvizi Surgical Innovation was founded in 2018 by Javad Parvizi, M.D. Its purpose is to “further advance healthcare for both the patient and provider with the collective knowledge of devoted clinicians, world-class surgeons, and scientists.” Dr. Parvizi is James Edward Professor of orthopedic surgery at the Rothman Orthopaedic Institute at Thomas Jefferson University in Philadelphia, where he serves as the director and vice chairman of research.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy